Skip to main content

Table 2 Patient, tumor, and treatment characteristics

From: Smoking is predictive of poorer distant metastasis-free and progression free-survival in soft tissue sarcoma patients treated with pre-operative radiotherapy or chemoradiotherapy

  Number of patients (%)
166
Median age Smoking: 60
Non-smoking: 55
Smoking No: 109 (65.6)
Yes: 57 (34.4)
Current smoker No: 143 (86.1)
Yes: 23 (13.9)
Cardiovascular disease No: 143 (86.1)
Yes: 23 (13.9)
Lung disease No: 147 (88.6)
COPD: 18 (10.8)
Primary malignancy: 1 (0.6)
Diabetes mellitus No: 145 (87.3)
Yes: 21 (12.7)
Grade Low: 16 (9.6)
Intermediate: 50 (30.1)
High: 100 (60.2)
Histology Undifferentiated/MFH: 45 (27.1)
Liposarcoma: 33 (19.9)
Synovial cell: 33 (19.9)
Myxofibrosarcoma: 23 (13.9)
Leiomyosarcoma: 15 (9.0)
MPNST: 6 (3.6)
Extraskeletal myxoid chondrosarcoma: 4 (2.4)
Fibrosarcoma: 3 (1.8)
Solitary fibrous: 3 (1.8)
Clear cell: 1 (0.6)
Stage I: 24 (14.4)
II: 25 (15.1)
III: 117 (70.5)
Karnofsky performance status 80–100: 141 (84.9)
≤ 70: 25 (15.1)
Tumor location Upper extremity: 39 (23.5)
Lower extremity: 127 (76.5)
Distant lung metastasis 42 (25.3)
Tumor size < 10 cm: 94 (56.6)
≥ 10 cm: 72 (43.4)
Chemotherapy No: 107 (64.5)
Yes: 59 (35.5)